foxo4 dri senolytic or senomorphic
foxo4 dri senolytic or senomorphic FOXO4-DRI Dosing: 1mg Protocol (2026) FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Targeting Cellular Senescence in Aging and Age Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies FOXO4 DRI UK Senolytic Peptide Research Peptides Lab UK The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology
USD23.06
USD45.06
Pay in 4 interest-free payments of $5.76 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
